The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

Learn more about AbbVie’s response to COVID-19

Woman in a blue dress smiles

skyrizi: an il-23
selective inhibitor1

SKYRIZI is a humanized immunoglobulin G1 (IgG1)
monoclonal antibody that1:

IL-23 is a key inflammatory driver in the pathogenesis of PsA and Ps.1-3

  • Selectively targets the p19 subunit of IL-23, a cytokine known to play a key role in driving inflammatory autoimmune diseases, such as
    PsA and Ps1,2
  • Blocks IL-23 from binding to its receptor, which inhibits the downstream release of additional key proinflammatory cytokines such as IL-17A, IL-17F, and IL-221-3

The mean half-life is approximately 28 days for a typical patient with PsA and Ps.1

The clinical significance of these findings is unknown. 

ACR20/50/70 RESPONSE RATES

In patients with PsA at Week 24 and 1 year1,4,5

Primary endpoint ACR 20 at 24 weeks

EXCEPTIONAL PATIENT ACCESS & SUPPORT

For your patients with PsA